Medical company Summit Medical Group said on Monday that the Department of Ear Nose & Throat/Allergy conducted a clinical trial that led the US Food & Drug Administration (FDA) to approve the nasal spay XHANCE (fluticasone proprionate) for the treatment of nasal polyps in patients 18 years of age or older.
The XHANCE clinical trial is reportedly part of the company's larger initiative to advance medicine.
Currently, the company is involved in 31 active clinical trials, which are critical to the development of new therapies, including finding innovative treatments for cancer, rheumatoid arthritis, type 2 diabetes as well as allergies.
In the US, about 10 million people suffer from the benign growths that block the nasal passages and cause congestion, pain and pressure, sinus infections and difficulty breathing.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT